Stock analysis · Bull Rankings model

PTCT analysis

PTC Therapeutics, Inc.Biotechnology. Scored on the same transparent model behind the daily rankings.

PTCT
PTC Therapeutics, Inc. · Biotechnology
FCF-$40mF
Rev-42.8%F
D/E
P/S5.8xB
PEG
24.7Score
$69.82$5.8B
1Y Target$99.29Analyst consensus · 14 analysts
5Y Target$173.65Compound horizon
10Y Target$310.35Long-dated conviction
FCF-$40mTTM
F
FCF is negative (-$40m) — cash-burning phase; acceptable only for pre-profit spec names
Rev-42.8%TTM YoY
F
Revenue -42.8% — severe decline
D/E
D/E data unavailable — neutral default
P/S5.8x
B
P/S 5.8x — near the Healthcare median (≈60th pctile)
PEG
PEG not meaningful — earnings growth negative or data unavailable

Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.

Quality-growth score · 24.7
Quality39.2
Growth14.7
Value26.0
Why this score
  • Diluting shareholders
Entry · Margin of safety
52-week rangeMid-range
23% off the 12-month high
Quality signals · context only
Gross profitability31% · B+gross profit ÷ total assets (Novy-Marx)

Model-generatedGenerated by the Bull Rankings model from this company's reported fundamentals, and checked against the figures shown above.

Why now
Biotechnology · market cap $5.8b. Down 23% from 52-week high of $90.87 — deep drawdown territory. Revenue -43% — in contraction; any catalyst that reverses this triggers re-rating. 14 sell-side analysts rate this a Buy with a mean 1-yr target of $99.29 (implying +42% upside).
Moat
ROE 23% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Free cash flow is negative (-$40m) — capital raises or debt issuance likely required; dilution / leverage risk. Revenue contracting -43% — the operational turn is not yet visible in the top line. Currently unprofitable (margin -3.8%) — path to GAAP profitability is the core thesis risk.
Horizon
1-3 yr $99.29 (14-analyst consensus) — catalyst-driven; binary events dominate. 5 yr $173.65 — requires the platform / technology to reach commercial scale. 10 yr $310.35 — return distribution heavily skewed.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.

PTCT vs the Top Picks average

PillarPTCTBook avgDiff
Quality0.390.84-0.45
Growth0.150.84-0.69
Value0.260.78-0.52

Averaged across the 30 names in today's Top Picks (mean score 81.5). A name can beat these averages and still be absent from the book — it also applies concentration limits.

Trend
-14.5 over 47 daily scores
From 39.2 (Jun 22) → 24.7 (now)

One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.

Analyst estimate revisions

30-day change-19.0%
90-day change-10.2%
Forward EPS estimate$2.50

Over the last 90 days, what analysts expect PTCT to earn is materially lower (-10.2%). The estimate is derived from price and forward P/E captured at the same instant, so a moving share price does not move this number — only a changed forecast does.

A rising estimate means expectations are improving, not that the price has failed to keep up — and estimates get cut as readily as they get raised. It is not part of the Bull Rankings score. Biggest movers across the market →

Shares to buy
28
Position size
$1,955
3.9% of portfolio
Stop price
$52.36
25% below $69.82
$ at risk if stopped
$488.74
budget $500.00 · 1% of portfolio

Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.

PTC Therapeutics, Inc. (PTCT): score, valuation & FAQ

PTC Therapeutics, Inc. (PTCT) is a Biotechnology company that scores 24.7 out of 100 on the Bull Rankings quality-growth model — a weak reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.

The model flags FCF (F) and Rev (F) as weaker areas.

Is PTCT a good stock to buy?

Bull Rankings scores PTCT 24.7 out of 100 on its quality-growth model, which is a weak reading. A score is a quantitative screen of PTC Therapeutics, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.

Why does PTCT score 24.7 on Bull Rankings?

The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). PTCT grades middle-of-pack across the strip, and is held back by FCF (F) and Rev (F). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.

Is PTCT overvalued or undervalued?

We don't compute a reliable discounted-cash-flow value for PTCT — typically because it is not yet consistently profitable or free-cash-flow positive — so its valuation rests on growth and price-to-sales rather than on earnings-based intrinsic value. Judge it on the trajectory of the business, not a single multiple.

What are the main risks of investing in PTCT?

Free cash flow is negative (-$40m) — capital raises or debt issuance likely required; dilution / leverage risk. Revenue contracting -43% — the operational turn is not yet visible in the top line. Currently unprofitable (margin -3.8%) — path to GAAP profitability is the core thesis risk.

New to these metrics? The guides explain free cash flow, how the score works, and more in the learn hub — or run another name through the screener.

Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial advisor.

More Biotechnology stocks by score

All Healthcare rankings →

Analyze another ticker →